According to the official website of the US Senate, the US FY2026 Defense Authorization Act, which includes the revised “Biosafety Act,” was voted on in the House of Representatives last week, and the US Senate decided to hold another meeting at 10:00 a.m. local time on the 17th to vote on bills such as the 2026 NDAA, which includes the revised “Biosafety Act.” The reporter checked the revised “Biosafety Act”. This version still does not specifically name any companies, but it is stipulated that in the future, the White House Office of Management and Budget will draw up a list of restricted companies within one year after the bill is passed, with reference to the US Department of Defense and other relevant lists. This is different from last year's multiple versions of the Biosafety Act, which directly named pharmaceutical companies such as Kangde.

According to the official website of the US Senate, the US FY2026 Defense Authorization Act, which includes the revised “Biosafety Act,” was voted on in the House of Representatives last week, and the US Senate decided to hold another meeting at 10:00 a.m. local time on the 17th to vote on bills such as the 2026 NDAA, which includes the revised “Biosafety Act.” The reporter checked the revised “Biosafety Act”. This version still does not specifically name any companies, but it is stipulated that in the future, the White House Office of Management and Budget will draw up a list of restricted companies within one year after the bill is passed, with reference to the US Department of Defense and other relevant lists. This is different from last year's multiple versions of the Biosafety Act, which directly named pharmaceutical companies such as Kangde.